Human Activin A Market By Type (IL-4, GM-CSF, and Others), By Applications (Commercial Research and Academic Research), By End User (Duloxetine HCl and Others), Industry Trends, Estimation & Forecast, 2023-2030

Market Overview

Activin A is a member of the TGF-β superfamily of cytokines, was originally identified as an inducer of follicle-stimulating hormone release, and it modulates the proliferation and differentiation of various target cells. Activin A is a disulfide-linked homodimer that binds to heteromeric complexes of type I and a type II serine-threonine kinase receptor. Activin A and its binding protein follistatin can be crucial in glucose homeostasis, as multifunctional proteins mediating inflammatory and anti-inflammatory effects. Human Activin A maintains the undifferentiated state of human embryonic stem cells and facilitates differentiation of human embryonic stem cells into definitive endoderm.

Human Activin A market was valued at 9.5 billion US$ in 2022 and is projected to reach 25.7 billion US$ by 2030, at a CAGR of 13.2% during the forecast period.

Market Dynamics

The increasing use of human activin A for renal damage in AAV patients is boosting the global human activin A market. According to the researches, measuring the levels of activin A protein in the urine can help clinicians identify patients with renal problems caused by antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Activin A is known to control kidney development and to block regeneration of renal tubules after injury in adult kidneys. However, increasing side effects from human activin A might hamper the market growth.

For instance, mild flu-like syndrome (fever, headache, generalized aches and pains, weakness and fatigue), swelling in hands and feet, shortness of breath, wheezing, difficulty breathing, closing up of the throat, swelling of facial features, hives. The severe condition from human activin A side effect such as fever of 100.4° F (38° C) or higher, chills, dizziness, sudden swelling or rapid weight gain, little or no urine output (for 8-12 hours), shortness of breath, difficulty breathing, irregular heartbeats, or chest pain needs immediate attention. Moreover, increasing use of human activin A in research activities would provide lucrative opportunities for the market in the coming years.

Market Segmentation

The global human activin A market is mainly classified based on type, applications, and end user. Type is further segmented into IL-4, GM-CSF, and Others. By applications, the market is divided into Commercial Research and Academic Research, and by end user, the market is further divided into Duloxetine HCl and Others.

Interleukin-4 (IL-4) is a pleiotropic cytokine produced in response to receptor activation by TH2-type CD4+ T cells, basophils, and mast cells. IL-4 is dominating the global human activin A market by type, due to the increase in clinical trials of IL-4 vaccine for the treatment of autoimmune diseases. For instance, Neovacs, a leader in active immunotherapies for the treatment of autoimmune diseases, is conducting clinical trial for patients with allergic asthma, with new IL-4 / IL-13 Kinoid therapeutic vaccine.

Regional Analysis

Based on geography, the global human activin A market is divided into North America, Europe, Asia-Pacific, South America, and Middle East & Africa. North America is further divided in the U.S., Canada, and Mexico. Europe consists of the UK, Germany, France, Italy, and Rest of Europe. Asia-Pacific is segmented into India, China, Japan, South Korea, and Rest of Asia-Pacific. The South America region includes Brazil, Argentina, and the Rest of South America, while the Middle East & Africa is categorized into GCC Countries, Egypt, South Africa, and Rest of Middle East & Africa.

North America was dominating the global human activin A market in 2019, due to the increasing clinical study of human activin A in human blood is boosting the North America human activin A market. For instance, Pieris Pharmaceuticals, Inc., has conducted a new clinical study on AZD1402/PRS-060, an inhaled Anticalin IL4-Rα antagonist, potently inhibits IL-4 induced functional effects in whole human blood.

North America’s human activin A market is estimated to reach 3,220.7 thousand US$ in 2019 with a CAGR of 14.6% from 2023 to 2030.

Competitive landscape

Key players operating in the human activin A industry include Ajinomoto, Thermo Fisher Scientific, Merck, STEMCELL, PeproTech, Bio-Techne, StemRD, Prospec, Proteintech Group, Enzo Biochem, Sino Biological, ReproCELL.

The facility expansion by the companies to develop human activin A is boosting the market growth. For instance, on June 20, 2019, Proteintech Group, Inc. has introduced its new state of the art Good Manufacturing Practice (GMP)-grade laboratory at the company’s headquarters in Rosemont, Illinois. The new facility focuses on the expansion of Proteintech’s GMP-grade Humankine line of human cell line-derived growth factors and cytokines for use in the pharmaceutical industry. Further, strategic acquisition between companies to solidify their position in the market is boosting the global human activin A market. For instance, on April 16, 2018, Proteintech Group, Inc. has signed an agreement to purchase HumanZyme. HumanZyme is one of the leading manufacturers of recombinant human proteins. Their proprietary human cell-expression system generates authentic human proteins that have greater biological activity and stability than competitors’ systems. With this acquisition, Proteintech Group further solidifies its position as a leading manufacturer of antibodies, proteins and ELISA kits.

Human Activin A Market Key Segments

By Type
• IL-4
• GM-CSF
• Others

By Applications
• Commercial Research
• Academic Research

By End-User
• Duloxetine HCl
• Others

Key Global Human Activin A Industry Players

• Ajinomoto
• Thermo Fisher Scientific
• Merck
• STEMCELL
• PeproTech
• Bio-Techne
• StemRD
• Prospec
• Proteintech Group
• Enzo Biochem
• Sino Biological
• ReproCELL

Table of Content

1. Market Introduction
1.1. Executive Summary
1.2. Market Definition
1.3. Market Scope

2. Research Methodology
2.1. Primary Research
2.2. Research Methodology
2.3. Assumptions & Exclusions
2.4. Secondary data sources

3. Human Activin A Market Overview
3.1. Report Segmentation & Scope
3.2. Key Market Trend
3.3. Drivers
3.3.1. Increasing use of Human Activin A for Renal Damage in AAV Patients
3.4. Restraints
3.4.1. Increasing Side Effects from Human Activin A
3.5. Opportunity
3.5.1. Increasing use of Human Activin A in Research Activities
3.6. Porter’s Five Forces Analysis
3.6.1. Porter’s Five Forces Analysis
3.7. Market Share Analysis

4. Type Overview
4.1. Introduction
4.1.1. Market Size & Forecast
4.2. IL-4
4.2.1. Market Size & Forecast
4.3. GM-CSF
4.3.1. Market Size & Forecast
4.4. Others
4.4.1. Market Size & Forecast

5. Applications Overview
5.1. Introduction
5.1.1. Market Size & Forecast
5.2. Commercial Research
5.2.1. Market Size & Forecast
5.3. Academic Research
5.3.1. Market Size & Forecast

6. End-User Overview
6.1. Introduction
6.1.1. Market Size & Forecast
6.2. Duloxetine HCl
6.2.1. Market Size & Forecast
6.3. Others
6.3.1. Market Size & Forecast

7. Human Activin A Market Regional Overview
7.1. Introduction
7.1.1. Market Size & Forecast
7.2. North America Human Activin A Market
7.2.1. North America Market Size & Forecast, By Country
7.2.2. North America Market Size & Forecast, By Type
7.2.3. North America Market Size & Forecast, By Applications
7.2.4. North America Market Size & Forecast, By End User
7.2.5. The U.S.
7.2.5.1. Market Size and Forecast
7.2.6. Canada
7.2.6.1. Market Size and Forecast
7.2.7. Mexico
7.2.7.1. Market Size and Forecast
7.3. Europe Human Activin A Market
7.3.1. Europe Market Size & Forecast, By Country
7.3.2. Europe Market Size & Forecast, By Type
7.3.3. Europe Market Size & Forecast, By Applications
7.3.4. Europe Market Size & Forecast, By End User
7.3.5. Germany
7.3.5.1. Market Size and Forecast
7.3.6. France
7.3.6.1. Market Size and Forecast
7.3.7. UK
7.3.7.1. Market Size and Forecast
7.3.8. Italy
7.3.8.1. Market Size and Forecast
7.3.9. Spain
7.3.9.1. Market Size and Forecast
7.3.10. Rest of Europe
7.3.10.1. Market Size and Forecast
7.4. Asia-Pacific Human Activin A Market
7.4.1. Asia-Pacific Market Size & Forecast, By Country
7.4.2. Asia-Pacific Market Size & Forecast, By Type
7.4.3. Asia-Pacific Market Size & Forecast, By Applications
7.4.4. Asia-Pacific Market Size & Forecast, By End User
7.4.5. Japan
7.4.5.1. Market Size and Forecast
7.4.6. China
7.4.6.1. Market Size and Forecast
7.4.7. Australia
7.4.7.1. Market Size and Forecast
7.4.8. India
7.4.8.1. Market Size and Forecast
7.4.9. South Korea
7.4.9.1. Market Size and Forecast
7.4.10. Rest of Asia-Pacific
7.4.10.1. Market Size and Forecast
7.5. South America Human Activin A Market
7.5.1. South America Market Size & Forecast, By Country
7.5.2. South America Market Size & Forecast, By Type
7.5.3. South America Market Size & Forecast, By Applications
7.5.4. South America Market Size & Forecast, By End User
7.5.5. Brazil
7.5.5.1. Market Size and Forecast
7.5.6. Argentina
7.5.6.1. Market Size and Forecast
7.5.7. Rest of South America
7.5.7.1. Market Size and Forecast
7.6. Middle East & Africa Human Activin A Market
7.6.1. Middle East & Africa Market Size & Forecast, By Country
7.6.2. Middle East & Africa Market Size & Forecast, By Type
7.6.3. Middle East & Africa Market Size & Forecast, By Applications
7.6.4. Middle East & Africa Market Size & Forecast, By End User
7.6.5. GCC Countries
7.6.5.1. Market Size and Forecast
7.6.6. Egypt
7.6.6.1. Market Size and Forecast
7.6.7. South Africa
7.6.7.1. Market Size and Forecast
7.6.8. Rest of Middle East & Africa
7.6.8.1. Market Size and Forecast

8. Company Profile
8.1. Ajinomoto
8.1.1. Company Basic Information, Manufacturing Base, Sales Area and Its Competitors
8.1.2. Ajinomoto Product Category, Application, and Specification
8.1.3. Ajinomoto Financial Performance (2016-2018)
8.1.4. Main Business/Business Overview
8.2. Thermo Fisher Scientific
8.3. Merck
8.4. STEMCELL
8.5. PeproTech
8.6. Bio-Techne
8.7. StemRD
8.8. Prospec
8.9. Proteintech Group
8.10. Enzo Biochem
8.11. Sino Biological
8.12. ReproCELL